Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Queen Mary University of London · Barts Health NHS Trust · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
738
total citations
- FWCI
- 60.41
- Percentile
- 100%
- References
- 23
Citations per year
Authors
20- TPThomas PowlesCorresponding
Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, University College London
- ERElizabeth R. Plimack
Fox Chase Cancer Center
- DSDenis Soulières
Centre Hospitalier de l’Université de Montréal
- TWTom Waddell
The Christie NHS Foundation Trust
- VSV.P. Stus
Ministry of Health, Dnipro State Medical University
Topics & keywords
Topics
Keywords
- Axitinib
- Medicine
- Sunitinib
- Renal cell carcinoma
- Pembrolizumab
- Interim analysis
- Internal medicine
- Clinical endpoint
No related works found for this paper.